Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2024.1353835 Immunology Correction Corrigendum: Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion AguirreGabriel A. 1 ‡ GoulartMichelle R. 1 ‡ BankBarts Pancreas Tissue 1 DalliJesmond 2 * † ‡ KocherHemant M. 1 * † ‡ 1Centre for Tumour Biology, Barts Cancer Institute, London, United Kingdom 2William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, Queen Mary University of London, London, United Kingdom

Edited and Reviewed by: Maarten Fokke Bijlsma, Academic Medical Center, Netherlands

*Correspondence: Hemant M. Kocher, h.kocher@qmul.ac.uk; Jesmond Dalli, j.dalli@qmul.ac.uk

†These authors have contributed equally to this work

‡ORCID: Gabriel A. Aguirre, orcid.org/0000-0003-4125-2661; Michelle R. Goulart, orcid.org/0000-0001-8333-3908; Jesmond Dalli, orcid.org/0000-0001-6328-3640; Hemant M. Kocher, orcid.org/0000-0001-6771-1905

24 01 2024 2024 15 1353835 11 12 2023 16 01 2024 Copyright © 2024 Aguirre, Goulart, Bank, Dalli and Kocher 2024 Aguirre, Goulart, Bank, Dalli and Kocher

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion by Aguirre GA, Goulart MR, Barts Pancreas Tissue Bank, Dalli J and Kocher HM (2023) Front. Immunol. 14:1248547. doi: 10.3389/fimmu.2023.1248547 pancreatic ductal adenocarcinoma specialized pro-resolving mediator lipid mediator cancer-associated fibroblast all-trans retinoic acid ALOX15 CAF subtypes Barts Charity10.13039/100015652 Pancreatic Cancer Research Fund10.13039/100011704 section-in-acceptance Cancer Immunity and Immunotherapy

In the published article, there was an error in the Supplementary Material: Supplementary Methods, Page 7, at the sentence: “Identification was conducted using published criteria, briefly a minimum of six diagnostic ions in total ion count EPI spectrum, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (Supplementary Figure 2). [41]. The correct material statement appears below.

“Identification was conducted using published criteria, matching retention time to synthetic or authentic standards, MRM peaks with  more than five data points, a signal-to-noise ratio > 3 (UK/MAP). In a subset of samples the identity of these mediators was further confirmed by matching a minimum of six diagnostic ions in total ion count EPI spectrum to that of a reference standard (Supplementary Figure 2). [41]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.